Executive chairman of the Irish drug testing firm, Cathal Friel, wants to be part of study which involves being infected by the virus.
The head of Open Orphan, the Irish drug trials and testing company, has said he has volunteered to be infected with a dose of Covid-19 as part of a human study into the virus.
Open Orphan’s subsidiary hVIVO won a £40 million (€44 million) contract with the British government last week which will see it conduct what is termed a human challenge trial, that will involve volunteers being given a strain of Covid-19.
Open Orphan (LON:ORPH) was founded in 2017, with the goal of rapidly building Europe’s leading pharma services company by a management team with extensive industry and financial expertise. The company comprises of two commercial specialist CRO services businesses (Venn Life Sciences and hVIVO) and is also developing a genomics data platform business (Genomic Health Data).